卡姆雷利祖马布加上阿帕蒂尼布用于先前治疗过的高级上腺皮质癌:单臂二期试验
Yu-Chun Zhu1, Zhi-Gong Wei2, Jing-Jing Wang2
1Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
Nature communications
|November 28, 2024
概括
这项研究表明,将camrelizumab (一种PD-1抑制剂) 与apatinib (一种VEGFR抑制剂) 结合起来,为晚期上腺皮质癌 (ACC) 提供了有前途的治疗方法,改善了对其他疗法没有反应的患者的反应率和存活率.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 药理学 药理学是指药理学的学科.
背景情况:
- 上皮层癌 (ACC) 是一种罕见的,具有攻击性的癌症,晚期的治疗选择有限.
- 目前的二线治疗方法,包括单剂免疫疗法,显示出不满意的结果.
- 对于患有晚期ACC的患者,有必要制定有效的治疗策略.
研究的目的:
- 在先前接受过治疗的晚期ACC患者中,评估与阿帕蒂尼布 (VEGFR抑制剂) 结合卡梅利祖马布 (PD-1抑制剂) 的疗效和安全性.
- 确定客观响应率 (ORR) 作为主要终点.
- 评估二次终点,包括无进展生存率 (PFS),整体生存率 (OS) 和安全概况.
主要方法:
- 进行了一项II期临床试验 (NCT04318730).
- 晚期ACC的21名患者至少接受了一剂卡梅利祖马布和阿帕蒂尼布.
- 评估了客观反应率 (ORR),无进展生存率 (PFS),总生存率 (OS) 和安全性.
主要成果:
- 该研究达到其主要终点,客观反应率 (ORR) 为52% (95% CI,30-74%).
- 疾病控制率 (DCR) 高达95% (95% CI,76-100%).
- 中位数PFS为13.3个月,中位数OS为20.9个月. 常见的3-4级不良事件包括肝酶升高和淋巴衰竭.
结论:
- 卡姆雷利祖马布和阿帕蒂尼布的组合表明,在先前治疗的高级ACC中具有显著的疗效.
- 这种组合疗法代表了晚期上腺皮癌的潜在新治疗选择.
- 探索性分析表明,免疫细胞概况可以预测治疗反应.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


